Cargando…

An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro

A large number of prevalent lung diseases is associated with tissue inflammation. Clinically, corticosteroid therapies are applied systemically or via inhalation for the treatment of lung inflammation, and a number of novel therapies are being developed that require preclinical testing. In alveoli,...

Descripción completa

Detalles Bibliográficos
Autores principales: Drasler, Barbara, Karakocak, Bedia Begum, Tankus, Esma Bahar, Barosova, Hana, Abe, Jun, Sousa de Almeida, Mauro, Petri-Fink, Alke, Rothen-Rutishauser, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471931/
https://www.ncbi.nlm.nih.gov/pubmed/32974315
http://dx.doi.org/10.3389/fbioe.2020.00987
_version_ 1783578873083985920
author Drasler, Barbara
Karakocak, Bedia Begum
Tankus, Esma Bahar
Barosova, Hana
Abe, Jun
Sousa de Almeida, Mauro
Petri-Fink, Alke
Rothen-Rutishauser, Barbara
author_facet Drasler, Barbara
Karakocak, Bedia Begum
Tankus, Esma Bahar
Barosova, Hana
Abe, Jun
Sousa de Almeida, Mauro
Petri-Fink, Alke
Rothen-Rutishauser, Barbara
author_sort Drasler, Barbara
collection PubMed
description A large number of prevalent lung diseases is associated with tissue inflammation. Clinically, corticosteroid therapies are applied systemically or via inhalation for the treatment of lung inflammation, and a number of novel therapies are being developed that require preclinical testing. In alveoli, macrophages and dendritic cells play a key role in initiating and diminishing pro-inflammatory reactions and, in particular, macrophage plasticity (M1 and M2 phenotypes shifts) has been reported to play a significant role in these reactions. Thus far, no studies with in vitro lung epithelial models have tested the comparison between systemic and direct pulmonary drug delivery. Therefore, the aim of this study was to develop an inflamed human alveolar epithelium model and to test the resolution of LPS-induced inflammation in vitro with a corticosteroid, methylprednisolone (MP). A specific focus of the study was the macrophage phenotype shifts in response to these stimuli. First, human monocyte-derived macrophages were examined for phenotype shifts upon exposure to lipopolysaccharide (LPS), followed by treatment with MP. A multicellular human alveolar model, composed of macrophages, dendritic cells, and epithelial cells, was then employed for the development of inflamed models. The models were used to test the anti-inflammatory potency of MP by monitoring the secretion of pro-inflammatory mediators (interleukin [IL]-8, tumor necrosis factor-α [TNF-α], and IL-1β) through four different approaches, mimicking clinical scenarios of inflammation and treatment. In macrophage monocultures, LPS stimulation shifted the phenotype towards M1, as demonstrated by increased release of IL-8 and TNF-α and altered expression of phenotype-associated surface markers (CD86, CD206). MP treatment of inflamed macrophages reversed the phenotype towards M2. In multicellular models, increased pro-inflammatory reactions after LPS exposure were observed, as demonstrated by protein secretion and gene expression measurements. In all scenarios, among the tested mediators the most pronounced anti-inflammatory effect of MP was observed for IL-8. Our findings demonstrate that our inflamed multicellular human lung model is a promising tool for the evaluation of anti-inflammatory potency of drug candidates in vitro. With the presented setup, our model allows a meaningful comparison of the systemic vs. inhalation administration routes for the evaluation of the efficacy of a drug in vitro.
format Online
Article
Text
id pubmed-7471931
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74719312020-09-23 An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro Drasler, Barbara Karakocak, Bedia Begum Tankus, Esma Bahar Barosova, Hana Abe, Jun Sousa de Almeida, Mauro Petri-Fink, Alke Rothen-Rutishauser, Barbara Front Bioeng Biotechnol Bioengineering and Biotechnology A large number of prevalent lung diseases is associated with tissue inflammation. Clinically, corticosteroid therapies are applied systemically or via inhalation for the treatment of lung inflammation, and a number of novel therapies are being developed that require preclinical testing. In alveoli, macrophages and dendritic cells play a key role in initiating and diminishing pro-inflammatory reactions and, in particular, macrophage plasticity (M1 and M2 phenotypes shifts) has been reported to play a significant role in these reactions. Thus far, no studies with in vitro lung epithelial models have tested the comparison between systemic and direct pulmonary drug delivery. Therefore, the aim of this study was to develop an inflamed human alveolar epithelium model and to test the resolution of LPS-induced inflammation in vitro with a corticosteroid, methylprednisolone (MP). A specific focus of the study was the macrophage phenotype shifts in response to these stimuli. First, human monocyte-derived macrophages were examined for phenotype shifts upon exposure to lipopolysaccharide (LPS), followed by treatment with MP. A multicellular human alveolar model, composed of macrophages, dendritic cells, and epithelial cells, was then employed for the development of inflamed models. The models were used to test the anti-inflammatory potency of MP by monitoring the secretion of pro-inflammatory mediators (interleukin [IL]-8, tumor necrosis factor-α [TNF-α], and IL-1β) through four different approaches, mimicking clinical scenarios of inflammation and treatment. In macrophage monocultures, LPS stimulation shifted the phenotype towards M1, as demonstrated by increased release of IL-8 and TNF-α and altered expression of phenotype-associated surface markers (CD86, CD206). MP treatment of inflamed macrophages reversed the phenotype towards M2. In multicellular models, increased pro-inflammatory reactions after LPS exposure were observed, as demonstrated by protein secretion and gene expression measurements. In all scenarios, among the tested mediators the most pronounced anti-inflammatory effect of MP was observed for IL-8. Our findings demonstrate that our inflamed multicellular human lung model is a promising tool for the evaluation of anti-inflammatory potency of drug candidates in vitro. With the presented setup, our model allows a meaningful comparison of the systemic vs. inhalation administration routes for the evaluation of the efficacy of a drug in vitro. Frontiers Media S.A. 2020-08-21 /pmc/articles/PMC7471931/ /pubmed/32974315 http://dx.doi.org/10.3389/fbioe.2020.00987 Text en Copyright © 2020 Drasler, Karakocak, Tankus, Barosova, Abe, Sousa de Almeida, Petri-Fink and Rothen-Rutishauser. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Drasler, Barbara
Karakocak, Bedia Begum
Tankus, Esma Bahar
Barosova, Hana
Abe, Jun
Sousa de Almeida, Mauro
Petri-Fink, Alke
Rothen-Rutishauser, Barbara
An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro
title An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro
title_full An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro
title_fullStr An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro
title_full_unstemmed An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro
title_short An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs in vitro
title_sort inflamed human alveolar model for testing the efficiency of anti-inflammatory drugs in vitro
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471931/
https://www.ncbi.nlm.nih.gov/pubmed/32974315
http://dx.doi.org/10.3389/fbioe.2020.00987
work_keys_str_mv AT draslerbarbara aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT karakocakbediabegum aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT tankusesmabahar aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT barosovahana aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT abejun aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT sousadealmeidamauro aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT petrifinkalke aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT rothenrutishauserbarbara aninflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT draslerbarbara inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT karakocakbediabegum inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT tankusesmabahar inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT barosovahana inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT abejun inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT sousadealmeidamauro inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT petrifinkalke inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro
AT rothenrutishauserbarbara inflamedhumanalveolarmodelfortestingtheefficiencyofantiinflammatorydrugsinvitro